BMS-582949: crystalline form of a p38alpha inhibitor? WO2008079857.
The p38 kinases have long been recognized as potentially valuable targets in the development of novel anti-inflammatory therapies. An application claiming a single crystalline form of N-(5-(cyclopropylcarbamoyl)-2-methylphenyl)-5-methyl-1-(3-(trifluoromethyl)pyridin-2-yl)-1H-pyrazole-4-carboxamide and its therapeutic use for the treatment of inflammatory diseases including rheumatoid arthritis, psoriasis and atherosclerosis points to the claimed compound being a development compound. The available evidence suggests that the compound could be BMS-582949, a compound in Phase II studies for the treatment of rheumatoid arthritis, psoriasis and atherosclerosis.